Type B Insulin Resistance in Peru

Manrique, Helard; Zelada, Henry; Arbanil, Hugo; Gamarra, Dante

dc.contributor.author	Zelada, Henry
dc.contributor.author	Gamarra, Dante
dc.contributor.author	Arbanil, Hugo
dc.contributor.author	Manrique, Helard
dc.date.accessioned	2019-01-25T17:00:30Z
dc.date.available	2019-01-25T17:00:30Z
dc.date.issued	2016
dc.identifier.uri	https://hdl.handle.net/20.500.12866/4964
dc.description.abstract	Type B insulin resistance (IR) is a rare autoimmune disease characterized by the presence of insulin receptor autoantibodies, resulting in a marked IR inducing hyperglycemia. Our first case is a 42-year-old female with a history of RA, SLE and Hashimoto-thyroiditis that presented with cachexia, acanthosis-nigricans, hirsutism, negative anti-insulin-ab and glucose level between 400 to 700 mg/dl, despite a total insulin dose of 1000 IU/day. She received pulses of cyclophosphamide along with prednisone. One year later the patient was off insulin and with HbA1c of 5.6%. The second case is a 42-year-old female patient that presented with polyuria, polydipsia, cachexia, acanthosis-nigricans, negative glutamic-acid-decarboxilase-ab and positive TPO-ab. She received IV infusion of regular insulin at a rate of 500 UI/d. Two years later she was off insulin with HbA1C of 5.6%. As summary, we reported a case of a disease remitted after receiving immunosuppressive therapy and a case of disease remitted spontaneously.	en_US
dc.language.iso	eng
dc.publisher	Elsevier
dc.relation.ispartofseries	American Journal of the Medical Sciences
dc.rights	info:eu-repo/semantics/restrictedAccess
dc.rights.uri	https://creativecommons.org/licenses/by-nc-nd/4.0/deed.es
dc.subject	Developing country	en_US
dc.subject	Immunosuppressive therapy	en_US
dc.subject	Insulin resistance	en_US
dc.subject	Insulin Resistance	en_US
dc.subject	Latin America	en_US
dc.subject	Peru	en_US
dc.subject	Adult	en_US
dc.subject	Autoantibodies/immunology	en_US
dc.subject	Autoimmune Diseases/drug therapy/immunology	en_US
dc.subject	Cyclophosphamide/administration & dosage/therapeutic use	en_US
dc.subject	Drug Therapy, Combination	en_US
dc.subject	Female	en_US
dc.subject	Humans	en_US
dc.subject	Immunosuppressive Agents/administration & dosage/therapeutic use	en_US
dc.subject	Peru	en_US
dc.subject	Prednisone/administration & dosage/therapeutic use	en_US
dc.subject	Receptor, Insulin/immunology	en_US
dc.subject	Remission Induction	en_US
dc.title	Type B Insulin Resistance in Peru	en_US
dc.type	info:eu-repo/semantics/article
dc.identifier.doi	https://doi.org/10.1016/j.amjms.2016.07.001
dc.subject.ocde	https://purl.org/pe-repo/ocde/ford#3.02.18
dc.relation.issn	1538-2990